Hansa Biopharma interim report Jan-Sep 2020

Author's Avatar
Oct 22, 2020
Article's Main Image

Hansa Biopharma advances to commercial stage following conditional EU approval of Idefirix; Positive high-level data from investigator-initiated phase 2 trial with imlifidase in anti-GBM

PR Newswire